Janux Therapeutics Stock Options
| JANX Stock | USD 29.94 0.49 1.61% |
Janux Therapeutics' latest option contracts expiring on June 20th 2025 are carrying combined implied volatility of 0.85 with a put-to-call open interest ratio of 0.93 over 20 outstanding agreements suggesting investors are buying slightly more calls than puts on contracts expiring on June 20th 2025.
Open Interest Against June 20th 2025 Option Contracts
Janux Therapeutics option prices can potentially be used to forecast stock returns because most option chains provide information not only about the current prices but also about the future conditions in Janux Therapeutics' lending market. For example, when Janux Therapeutics' puts are not actively trading or completely missing in the marketplace, investors can use it to internalize expected shorting costs. So if an investor is writing a put option on Janux Therapeutics, he or she must hedge the risk by shorting Janux Therapeutics stock over its option's life.
2025-06-20
The chart above shows Janux Therapeutics' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Janux Therapeutics' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Janux Therapeutics' option, there is no secondary market available for investors to trade.
Janux Therapeutics Maximum Pain Price Across 2025-06-20 Option Contracts
Max pain occurs when Janux Therapeutics' market makers reach a net positive position across all Janux Therapeutics' options at a strike price where option holders stand to lose the most money. By contrast, Janux Therapeutics' option sellers may reap the most after selling more options than buying, causing them to expire worthless.
In The Money vs. Out of Money Option Contracts on Janux Therapeutics
Analyzing Janux Therapeutics' in-the-money options over time can help investors to take a profitable long position in Janux Therapeutics regardless of its overall volatility. This is especially true when Janux Therapeutics' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Janux Therapeutics' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Janux Therapeutics' stock while costing only a fraction of its price.
Janux Therapeutics In The Money Call Balance
When Janux Therapeutics' strike price is surpassing the current stock price, the option contract against Janux Therapeutics stock is said to be in the money. When it comes to buying Janux Therapeutics' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Janux Therapeutics are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Janux Current Options Market Mood
Janux Therapeutics' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Janux Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most Janux Therapeutics' options investors are not very successful. Janux Therapeutics' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Janux contract
Base on the Rule 16, the options market is currently suggesting that Janux Therapeutics will have an average daily up or down price movement of about 0.0531% per day over the life of the 2025-06-20 option contract. With Janux Therapeutics trading at USD 29.94, that is roughly USD 0.0159. If you think that the market is fully incorporating Janux Therapeutics' daily price movement you should consider buying Janux Therapeutics options at the current volatility level of 0.85%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Janux |
Purchasing Janux Therapeutics options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Janux calls. Remember, the seller must deliver Janux Therapeutics stock to the call owner when a call is exercised.
Janux Therapeutics Option Chain
When Janux Therapeutics' strike price is surpassing the current stock price, the option contract against Janux Therapeutics stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Janux Therapeutics' option chain is a display of a range of information that helps investors for ways to trade options on Janux. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Janux. It also shows strike prices and maturity days for a Janux Therapeutics against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | JANX250620C00055000 | 1 | 55.0 | 0.0 - 2.45 | 0.9 | Out |
Call | JANX250620C00050000 | 1 | 50.0 | 0.0 - 2.8 | 1.0 | Out |
Call | JANX250620C00045000 | 6 | 45.0 | 0.0 - 1.75 | 1.6 | Out |
Call | JANX250620C00040000 | 6 | 40.0 | 0.0 - 3.8 | 3.0 | Out |
Call | JANX250620C00035000 | 5 | 35.0 | 0.95 - 4.8 | 5.0 | Out |
Call | JANX250620C00030000 | 10 | 30.0 | 3.0 - 6.8 | 6.0 | Out |
Call | JANX250620C00025000 | 0 | 25.0 | 5.7 - 9.5 | 5.7 | In |
Call | JANX250620C00022500 | 0 | 22.5 | 7.4 - 11.2 | 7.4 | In |
Call | JANX250620C00020000 | 0 | 20.0 | 9.3 - 13.0 | 9.3 | In |
Call | JANX250620C00017500 | 0 | 17.5 | 11.2 - 15.2 | 11.2 | In |
Put | JANX250620P00055000 | 0 | 55.0 | 23.0 - 27.5 | 23.0 | In |
Put | JANX250620P00050000 | 2 | 50.0 | 18.2 - 22.2 | 19.9 | In |
Put | JANX250620P00045000 | 0 | 45.0 | 13.8 - 17.5 | 13.8 | In |
Put | JANX250620P00040000 | 0 | 40.0 | 9.3 - 13.2 | 9.3 | In |
Put | JANX250620P00035000 | 5 | 35.0 | 5.5 - 9.4 | 4.65 | In |
Put | JANX250620P00030000 | 10 | 30.0 | 2.3 - 6.3 | 3.76 | Out |
Put | JANX250620P00025000 | 10 | 25.0 | 0.5 - 4.1 | 1.85 | Out |
Put | JANX250620P00022500 | 0 | 22.5 | 0.0 - 3.2 | 3.2 | |
Put | JANX250620P00020000 | 0 | 20.0 | 0.0 - 2.7 | 2.7 | |
Put | JANX250620P00017500 | 0 | 17.5 | 0.0 - 2.35 | 2.35 |
Janux Total Stockholder Equity
Total Stockholder Equity |
|
Janux Therapeutics Corporate Management
| Brenda Vreeswyk | Head Resources | Profile | |
| Zachariah DO | Chief Officer | Profile | |
| Wayne MD | Chief Officer | Profile | |
| Matt Whitmire | Vice Finance | Profile | |
| Charles Winter | Manufacturing Chemistry | Profile | |
| CFA CPA | Acting Officer | Profile | |
| Andy Meyer | Chief Officer | Profile |
Additional Tools for Janux Stock Analysis
When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.